Drug Profile
Research programme: oral cavity disorder biotherapeutics - Precigen Inc/Oragenics
Latest Information Update: 11 Feb 2020
Price :
$50
*
At a glance
- Originator Intrexon Corporation; Oragenics Inc
- Developer Oragenics Inc; Precigen Inc
- Class
- Mechanism of Action Mucoprotein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mouth disorders; Stomatitis
Most Recent Events
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 28 Jul 2019 No recent reports of development identified for research development in Mouth-disorders in USA
- 28 Jul 2019 No recent reports of development identified for research development in Stomatitis in USA